Unlocking The Molecular Mechanism of Pathogenic and Non-pathogenic Th17 cells with InTraSeq

Webinar: Unlocking The Molecular Mechanism of Pathogenic and Non-pathogenic Th17 cells with InTraSeq.

PROGRAMME:

15:00 - 15:05: Introduction

15:05 - 15:25: Dr. Maxime Jacquet introduces CST, validation and InTraSeq

15:25 - 15:50: Presentation by Majd Ariss, PhD, MS

15:50 - 16:00: Q&A

ABSTRACT: 

Single-cell RNA sequencing (scRNA-seq) provides a partial view of cellular function. To address this, InTraSeq enables the simultaneous measurement of mRNA, surface, cytoplasmic, and nuclear proteins within individual cells. This multimodal approach offers a comprehensive view of cellular function by combining RNA and protein profiling from the same sample. InTraSeq allows researchers to expand their view of critical intracellular protein expression, including post-translational modifications (PTMs) and transcription factors. This is valuable for understanding cell population heterogeneity and identifying distinct functional states. We used InTraSeq to characterize Th17 cell differentiation, simultaneously profiling RNA and protein expression in over 85,000 cells. Our results revealed novel insights into Th17 cell differentiation, including the identification of key regulatory factors and their target genes. By simultaneously measuring mRNA, extra and intra-cellular proteins, signaling proteins, and PTMs, InTraSeq offers a comprehensive understanding of cellular processes and enables the identification of novel regulatory mechanisms.

FEATURES SPEAKERS:

Dr. Maxime Jacquet         

Earned his PhD at the University of Neuchâtel, Switzerland, where he focused on the transmission dynamics of the Lyme disease agent, Borrelia afzelii. His postdoctoral journey began at the University of Pennsylvania in Philadelphia, working in Chris Hunter's lab to elucidate the role of GM-CSF in inflammation. Returning to Switzerland, Maxime deepened his immunology expertise during a second postdoc at the University of Basel. In July 2022, he joined Cell Signaling Technology (CST) as a Field Application Scientist. In this role, he leverages his extensive knowledge in immunology, flow cytometry, immunofluorescence, and other applications to support CST users across Europe.

Majd Ariss, PhD, MS

is a Principal Scientist at Cell Signaling Technology and a leading expert in single-cell research. He developed InTraSeq Single Cell Analysis, a groundbreaking method for simultaneously measuring RNA and proteins in individual cells, including post-translational modifications. Dr. Ariss has authored and co-authored numerous research publications, including three first-author publications on the application of single-cell technologies. He received his BS and MS in Biochemistry and Molecular Biology from the American University of Beirut and Georgetown University, respectively, and his PhD from the University of Illinois Chicago, where he was among the first researchers in the state to utilize high-throughput single-cell RNA sequencing (scRNA-seq) technology, and he spearheaded the adoption of the Drop-Seq scRNA-seq platform. After earning his doctorate, Majd was a postdoctoral fellow at the Laboratory of Norbert Perrimon, Harvard Medical School, serving as the single-cell expert. He joined Cell Signaling Technology in 2021.